1. Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation. (1st June 2020) Authors: Dash, Ajeeta B.; Zhang, Jacob; Shen, Lei; Li, Bin; Berg, Deborah; Lin, Jianchang; Avet‐Loiseau, Hervé; Bahlis, Nizar J.; Moreau, Philippe; Richardson, Paul G.; Di Bacco, Alessandra Journal: European journal of haematology Issue: Volume 105:Number 3(2020) Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. C‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. (15th April 2020) Authors: Di Bacco, Alessandra; Bahlis, Nizar J.; Munshi, Nikhil C.; Avet‐Loiseau, Hervé; Masszi, Tamás; Viterbo, Luísa; Pour, Ludek; Ganly, Peter; Cavo, Michele; Langer, Christian; Kumar, Shaji K.; Rajkumar, S. Vincent; Keats, Jonathan J.; Berg, Deborah; Lin, Jianchang; Li, Bin; Badola, Sunita; Shen, Lei;... Journal: European journal of haematology Issue: Volume 105:Number 1(2020) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Disease burden of systemic light-chain amyloidosis: a systematic literature review. (3rd June 2017) Authors: Lin, Huamao Mark; Gao, Xin; Cooke, Catherine E.; Berg, Deborah; Labotka, Richard; Faller, Douglas V.; Seal, Brian; Hari, Parameswaran Journal: Current medical research and opinion Issue: Volume 33:Number 6(2017) Page Start: 1017 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Issue 22 (1st August 2021) Authors: Richardson, Paul G.; Kumar, Shaji K.; Masszi, Tamás; Grzasko, Norbert; Bahlis, Nizar J.; Hansson, Markus; Pour, Luděk; Sandhu, Irwindeep; Ganly, Peter; Baker, Bartrum W.; Jackson, Sharon R.; Stoppa, Anne-Marie; Gimsing, Peter; Garderet, Laurent; Touzeau, Cyrille; Buadi, Francis K.; Laubach, Jacob... Journal: Journal of clinical oncology Issue: Volume 39:Issue 22(2021) Page Start: 2430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. (3rd August 2018) Authors: Hari, Parameswaran; Lin, Huamao Mark; Zhu, Yanyan; Berg, Deborah; Richardson, Paul G.; Moreau, Philippe Journal: Journal of medical economics Issue: Volume 21:Number 8(2018) Page Start: 793 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. (8th May 2019) Authors: Dimopoulos, Meletios A.; Laubach, Jacob P.; Echeveste Gutierrez, Maria Asunción; Grzasko, Norbert; Hofmeister, Craig C.; San‐Miguel, Jesus F.; Kumar, Shaji; Labotka, Richard; Lu, Vickie; Berg, Deborah; Byrne, Catriona; Teng, Zhaoyang; Liu, Guohui; van de Velde, Helgi; Richardson, Paul G. Journal: European journal of haematology Issue: Volume 102:Number 6(2019) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. (9th May 2017) Authors: Kumar, Shaji; Moreau, Philippe; Hari, Parameswaran; Mateos, Maria‐Victoria; Ludwig, Heinz; Shustik, Chaim; Masszi, Tamas; Spencer, Andrew; Hájek, Roman; Romeril, Kenneth; Avivi, Irit; Liberati, Anna M.; Minnema, Monique C.; Einsele, Hermann; Lonial, Sagar; Berg, Deborah; Lin, Jianchang; Gupta, Ne... Journal: British journal of haematology Issue: Volume 178:Number 4(2017) Page Start: 571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Issue 2 (23rd March 2018) Authors: Gupta, Neeraj; Hanley, Michael J.; Diderichsen, Paul M.; Yang, Huyuan; Ke, Alice; Teng, Zhaoyang; Labotka, Richard; Berg, Deborah; Patel, Chirag; Liu, Guohui; van de Velde, Helgi; Venkatakrishnan, Karthik Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 2(2019) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma. Issue 8 (20th June 2018) Authors: Leleu, Xavier; Masszi, Tamas; Bahlis, Nizar J.; Viterbo, Luisa; Baker, Bartrum; Gimsing, Peter; Maisnar, Vladimir; Samoilova, Olga; Rosiñol, Laura; Langer, Christian; Song, Kevin; Izumi, Tohru; Cleeland, Charles; Berg, Deborah; Lin, Huamao Mark; Zhu, Yanyan; Skacel, Tomas; Moreau, Philippe; Richa... Journal: American journal of hematology Issue: Volume 93:Issue 8(2018:Aug.) Page Start: 985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The patient's perspective on the symptom and everyday life impact of AL amyloidosis. (2nd October 2015) Authors: Lin, Huamao Mark; Seldin, David; Hui, Ai-Min; Berg, Deborah; Dietrich, C. Noelle; Flood, Emuella Journal: Amyloid Issue: Volume 22:Number 4(2015:Dec.) Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗